Rockefeller Capital Management
URGN icon

Rockefeller Capital Management’s UroGen Pharma URGN Stock Holding History

Rockefeller Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.12K Hold
112
– – ﹤0.01% 4285
2026
Q1 		$2.01K Hold
112
– – ﹤0.01% 4412
2025
Q4 		$2.62K Buy
+112
New +$2.43K ﹤0.01% 4253
2022
Q3 		– Sell
-40
Closed – – 4389
2022
Q2 		$0 Buy
+40
New +$275 ﹤0.01% 4403

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Rockefeller Capital Management's URGN Position: Q2 2026 in Review

Rockefeller Capital Management held its UroGen Pharma (URGN) position steady in Q2 2026 at 112 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #4285.

Rockefeller Capital Management first reported a position in URGN in Q2 2022 and has held it in 4 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Rockefeller Capital Management held 112 shares of UroGen Pharma worth $4.12K as of Q2 2026.
  • Rockefeller Capital Management left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4285 holding.
  • Rockefeller Capital Management first reported a position in UroGen Pharma in Q2 2022 and has held it in 4 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.